Philadelphia University + Thomas Jefferson University

Active Opportunities

This list advertises funding opportunities from the NIH, NSF, DoD and other sponsors. 

List of Current Opportunities

November 2017

ORGANIZATION/ WEBSITE SPECIALTY
AREA
PURPOSE AWARD/DEADLINE

National Institute on Aging (NIA)

Go to site...

Aging and Geriatric Research The objective of the NIA Academic Leadership Career Award (K07) is to provide support for senior investigators who have the expertise and leadership skills to enhance aging and geriatric research capacity within their academic institution.

Award budgets are composed of salary and other program-related expenses. The total project period may not exceed 5 years.

Date: Standard dates, by 5:00 PM

National Institute on Drug Abuse (NIDA)

Go to site...

Substance Abuse and HIV/AIDS Avenir means future in French, and the Avenir Award Program for Research on Substance Abuse and HIV/AIDS looks toward the future by supporting early stage investigators (ESI) proposing highly innovative studies that address NIH HIV/AIDS Research Priorities https://grants.nih.gov/
grants/guide/notice-files/
NOT-OD-15-137.html. The Avenir Award Program for Research on Substance Abuse and HIV/AIDS will support creative individuals who wish to pursue innovative research at the nexus of substance abuse and HIV/AIDS. The nexus with drug abuse should be clearly described. The Avenir Award Program for Research on Substance Abuse and HIV/AIDS will support research approaches, both basic and clinical, which have the potential to benefit substance using populations with or at risk for HIV/AIDS by reducing HIV incidence, improving therapies for HIV, reducing the impact of comorbid conditions, and ultimately, eradicating HIV.

NIDA intends to commit $4M in FY 2018, 2019, 2020 to fund 2-3 awards each year. Awards are multi-year funded, with all funds being disbursed in the first year of the award. Awards will be up to $1,500,000 in direct costs (the equivalent of $300,000 in Direct Costs each year for five years) plus applicable Facilities and Administrative (F&A) costs to be determined at the time of award. The maximum project period is 4 years 6 months.

Date:  Nov 13, 2017; Nov 13, 2018, Nov 13, 2019 by 5:00 PM

National Institute on Minority Health and Health Disparities (NIMHD), National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Nursing Research (NINR)

Go to site...

Chronic Disease in the Caribbean Region, Caribbean immigrant populations in the US The purpose of this Funding Opportunity Announcement (FOA) is to support US-Caribbean collaborative research to develop or extend cohort or surveillance studies on chronic disease in the Caribbean region that are aligned with existing publicly available US datasets. The intent is for these cohorts or datasets to be used for ongoing comparative research to better understand the health of Caribbean immigrant populations in the US.

Application budgets are limited to $500,000 direct costs annually. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date:  November 15, 2017, November 15, 2018, November 15, 2019, by 5:00 PM

Department of Defense Defense Health Program Congressionally Directed Medical Research Programs Hearing Restoration Research Program

Go to site...

Hearing Restoration The FY17 HRRP TRA mechanism is being offered in this first year of the program to support preclinical translational research that will accelerate the movement of promising initiatives relevant to hearing restoration into clinical applications. Applications from investigators within the military Services, and applications involving multidisciplinary collaborations among academia, industry, the military Services, the VA, and other Federal Government agencies are highly encouraged. Though the HRRP supports groundbreaking and clinically relevant research, all projects must demonstrate solid scientific rationale.

The maximum period of performance is 3 years. The anticipated direct costs budgeted for the entire period of performance will not exceed $1M. The CDMRP expects to allot approximately $6.4M of the $10M FY17 HRRP appropriation to fund approximately 4 Translational Research Award applications, depending on the quality and number of applications received.

Date: 11:59 p.m. ET, November 15, 2017

Department of Defense Defense Health Program Congressionally Directed Medical Research Programs Hearing Restoration Research Program

Go to site...

Functional Hearing Restoration The FY17 HRRP FRA is intended to support functional hearing restoration research that develops and validates assessment techniques and treatment methods using patient-centric outcomes to identify potential predictive indicators for successful treatment of individuals living with functional auditory system deficits. The research in this area should result in refined diagnostic tools and improved evaluation of the effectiveness of therapeutic approaches. Applications involving multidisciplinary collaborations among academia, industry, the military Services, the VA, and other Federal Government agencies are highly encouraged. Under this award mechanism, research may support correlative or observational studies that are associated with an ongoing or completed clinical trial.

The maximum period of performance is 3 years. The anticipated direct costs budgeted for the entire period of performance will not exceed $750,000. The CDMRP expects to allot approximately $2.4M of the $10M FY17 HRRP appropriation to fund approximately 2 Focused Research Award applications, depending on the quality and number of applications received.

Date: 11:59 p.m. ET, November 15, 2017

National Cancer Institute (NCI)

Go to site...

Fusion Oncoproteins in Childhood Cancers This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research on fusion oncoproteins in childhood cancers. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation E. Intensify research on the major drivers of childhood cancers: Improve our understanding of fusion oncoproteins in pediatric cancer and use new preclinical models to develop inhibitors that target them. The goal of this FOA is to establish a consortium of collaborating research teams to advance our understanding of the biology and mechanisms of action of fusion oncoproteins in pediatric cancers, and to apply this knowledge towards developing targeted therapeutic approaches. Increased attention to this important but understudied field can help overcome existing barriers to progress and pave the way to novel therapeutic approaches with increased efficacy and fewer side effects than current options. The research teams comprising the Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium will take a comprehensive approach to understanding the biology of fusion oncoproteins in childhood cancers and will use this information to inform strategies for therapeutic targeting.

The NCI intends to commit approximately $7 million dollars total cost in FY 2018, contingent upon receiving scientifically meritorious applications. Up to 3 awards are anticipated from this solicitation. Application budgets are limited to $2.5 million total costs per year, and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: November 15, 2017, by 5:00 PM

National Institute of Neurological Disorders and Stroke (NINDS)

Go to site...

Epilepsy The purpose of this Funding Opportunity Announcement (FOA) is to encourage cooperative agreement (U54) applications from multidisciplinary groups of investigators to accelerate the rate of progress in determining the functional, pharmacological, neuronal network and whole animal consequences of genetic variants discovered in patients with various types of epilepsy and to develop strategies for establishing diagnostic criteria and identifying potential targets for intervention.

NINDS intends to commit $3,000,000 direct costs in FY 2018 to fund up to two awards at $1,500,000 direct costs each. Application budgets are limited to $1,500,000 direct costs per year. The scope of the proposed CWOW should determine the project period. The maximum project period is 5 years.

Date: November 15, 2017, by 5:00 PM

Department of Defense Defense Medical Research and Development Program

Go to site...

Neuromusculoskeletal Injury The FY17-18 JPC-8/CRMRP NMSIRRA is intended to support preclinical research, clinical
studies, and clinical trials on the reintegration after injury, functional utility of assistive devices
related to the human-device interface, secondary health effects following severe extremity injury,
optimizing rehabilitation and device prescription, and standardized assessment metrics for
patients with neuromusculoskeletal injury.

It is the responsibility of the PI to select the funding level that is most appropriate for the proposed research project. The requested budget level should be appropriate for the scope of research proposed. For Research Level 1/New Investigator Applications: The maximum period of performance is 3 years. The total costs budgeted for the entire period of performance will not exceed $600,000. For Research Level 2 Applications: The maximum period of performance is 4 years. The total costs budgeted for the entire period of performance will not exceed $2,500,000.The JPC-8/CRMRP expects to allot approximately $10M of the FY17-18 DHP RDT&E appropriation to fund approximately four Level 1 and three Level 2 Award applications, depending on the quality and number of applications received. Funding of applications received in response to this Program Announcement/Funding Opportunity is contingent upon the availability of Federal funds for this program. As of the release date of this Program Announcement/Funding Opportunity, the FY17 and FY18 Defense Appropriations Bills have not been passed, and there is no guarantee that any additional funds will be made available to support this program. The funding estimated for this Program Announcement/ Funding Opportunity is approximate and subject to realignment. Funding of applications received in response to this Program Announcement/ Funding Opportunity is contingent upon the
availability of Federal funds for this program.

Date: 11:59 p.m. ET, November 16, 2016

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Go to site...

Alcohol-induced Effects on Tissue Injury and Repair
 
This Funding Opportunity Announcement (FOA) encourages Exploratory/ Developmental Research Grant Award (R21) applications to study molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. Excessive alcohol consumption has the potential to adversely affect multiple organ systems including the liver, brain, heart, pancreas, lung, kidney, endocrine and immune systems, as well as bone and skeletal muscle. In addition, there is accumulating evidence that long term alcohol consumption is associated with reduced host capacity for recovery and repair following trauma. The mechanisms for these alcohol-induced effects on tissue injury and repair are currently not fully understood. NIAAA is especially interested in integrative research that elucidates alcohol’s effects on complex mechanisms of injury and repair that are either common or specific to each organ system. This FOA also encourages the study of alcohol’s effect on stem cells, embryonic development, and regeneration. Also encourages are studies on molecular and cellular actions of moderate alcohol consumption. A better understanding of these underlying mechanisms may provide new avenues for developing more effective and novel approaches for prognosis, diagnosis, intervention, and treatment of alcohol-induced organ damage.

The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The maximum project period is two years.

Date: Standard dates apply, by 5:00 PM

National Institute of Mental Health (NIMH)

Go to site...

Complex Brain Disorders, Neuronal Function This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function.  The present announcement seeks R21 applications.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed 2 years.   

Date: Standard dates apply, by 5:00 PM

National Institute on Aging (NIA), National Cancer Institute (NCI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR)

Go to Site...

HIV and Aging This FOA encourages exploratory/ developmental research applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Applications appropriate to this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-15-137.

The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The maximum project period is 2 years.

Date: Standard dates apply, by 5:00 PM

National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Environmental Health Sciences (NIEHS), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD)

Go to site...

Human Genome Research This Funding Opportunity Announcement (FOA) invites Exploratory/ Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research.  These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies.  Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.

Application budgets are limited to a combined total of no more than $275,000 in direct costs for the two year project. The scope of the proposed project should determine the project period.  The maximum project period is 2 years.

Date: Standard dates apply, by 5:00 PM

National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Environmental Health Sciences (NIEHS), Fogarty International Center (FIC)

Go to site...

  This Funding Opportunity Announcement (FOA) invites Small Research Grant (R03) applications to study the ethical, legal and social implications (ELSI) of human genome research.  These applications should be for small, self-contained research projects, such as those that involve single investigators.  Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues.  This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data. Application budgets are limited to no more than $50,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

Date: Standard dates apply, by 5:00 PM
 

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Go to site...

Secondary Analyses of Existing Alcohol Research Data  This Funding Opportunity Announcement (FOA) encourages the submission of investigator-initiated research grant applications to support the secondary analysis of existing data sets with the goal of enhancing our understanding of patterns of alcohol consumption, the epidemiology and etiology, including genetics, of alcohol-related problems.  Research grants for the Secondary Analyses of Existing Alcohol Research Data are intended to provide support for studies that utilize currently available data sets to increase our understanding of the incidence, prevalence and etiology of alcohol related problems and disorders in the population, as well as the risk and protective factors associated with them. Research that employs analytic techniques which demonstrate or promote methodological advances in alcohol-related epidemiologic and Genetics/Genomics research is also of interest.

Application budgets are limited to $50,000 in direct costs per year. The total project period may not exceed two years.

Date: Standard dates apply, by 5:00 PM

 

National Institute of Allergy and Infectious Diseases (NIAID)

Go to site...

Primary Immunodeficiency Diseases This Funding Opportunity Announcement (FOA) will support small grants on primary immunodeficiency diseases focusing on ex vivo studies with human specimens and on studies with current or new animal models including novel clinical strategies for detecting, identifying the molecular basis of, or developing innovative therapies for primary immunodeficiency diseases. In addition, this FOA aims to encourage analyses of clinical data and samples maintained in primary immunodeficiency registries, consortium databases and repositories to address questions relevant to primary immunodeficiency research.   The R03 grant supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources. Investigators who have not received independent NIH funding or independent NIH funding in this field are encouraged to apply to this FOA.

A budget for direct costs of up to $50,000 per year may be requested (i.e., a maximum of $100,000 over two years). The project period may not exceed 2 years.

Date: Standard dates apply, by 5:00 PM 

 

National Institute of Allergy and Infectious Diseases (NIAID)

Go to site...

Primary Immunodeficiency Diseases

This Funding Opportunity Announcement (FOA) will support innovative exploratory/developmental investigations on primary immunodeficiency diseases focusing on ex vivo studies with human specimens and on studies with current or new animal models including novel clinical strategies for detecting, identifying the molecular basis of, or developing innovative therapies for primary immunodeficiency diseases. In addition, this FOA aims to encourage analyses of clinical data and samples maintained in primary immunodeficiency registries, consortium databases and repositories to address questions relevant to primary immunodeficiency research.

 

Direct costs are limited to $275,000 over the two-year project period, with no more than $200,000 in direct costs allowed in any single year. The project period may not exceed 2 years.

Date: Standard dates apply, by 5:00 PM 

 

National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Environmental Health Sciences (NIEHS), Fogarty International Center (FIC)

Go to site...

Ethical, Legal and Social Implications (ELSI) of Human Genome Research

This Funding Opportunity Announcement (FOA) invites Small Research Grant (R03) applications to study the ethical, legal and social implications (ELSI) of human genome research.  These applications should be for small, self-contained research projects, such as those that involve single investigators.  Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues.  This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data.

 

Application budgets are limited to no more than $50,000 in direct costs per year. The scope of the proposed project should determine the project period.  The maximum project period is 2 years.

Date: Standard dates apply, by 5:00 PM 

 

National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Environmental Health Sciences (NIEHS), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD)

Go to site...

Ethical, Legal and Social Implications (ELSI) of Human Genome Research

This Funding Opportunity Announcement (FOA) invites Exploratory/ Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research.  These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies.  Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.

 

Application budgets are limited to a combined total of no more than $275,000 in direct costs for the two year project, with no more than $200,000 in direct costs in a single year. The scope of the proposed project should determine the project period.  The maximum project period is 2 years.

Date: Standard dates apply, by 5:00 PM 

 


National Science Foundation (NSF)

Go to site...

Cellular Dynamics and Function, Genetic Mechanisms, Molecular Biophysics, Systems and Synthetic Biology.

The Division of Molecular and Cellular Biosciences (MCB) supports quantitative, mechanistic, predictive, and theory-driven fundamental research designed to promote understanding of complex living systems at the molecular, subcellular, and cellular levels. While recognizing the need for thorough and accurate descriptions of biological complexes and pathways, the priority of the Division is to support work that advances the field by capturing the predictive power of mechanistic, quantitative, and evolutionary approaches. MCB is soliciting proposals in four core clusters: Cellular Dynamics and Function; Genetic Mechanisms; Molecular Biophysics; Systems and Synthetic Biology.

 

Estimated Number of Awards: 110. Anticipated Funding Amount: $83,000,000. Pending availability of funds, approximately $83M will be committed for the total budget of all new awards in each cycle.

Date: (due by 5 p.m. submitter's local time): November 20, 2017

 

National Institute of General Medical Sciences (NIGMS)

Go to site... 

Biomeedical/ Clinical/ Behavioral Workforce Education/ Training The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIGMS R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To this end, this funding opportunity announcement (FOA) encourages the development of innovative educational activities for pre-kindergarten to grade 12 (P-12), pre-service and in-service teachers (Teachers) and students from underserved communities with a focus on Courses for Skills Development, Research Experiences, Mentoring Activities, Curriculum or Methods Development and Outreach.

NIGMS intends to commit an estimated total of $2,000,000. Direct costs are limited to $250,000 annually. The SEPA project period is 5 years.

Date: November 20, 2017; July 9, 2018; July 9, 2019 , by 5:00 PM

 
National Cancer Institute (NCI) Cancer Nanotechnology This Funding Opportunity Announcement (FOA) encourages applications for the development of innovative research projects in cancer nanotechnology. This initiative, to be known as Innovative Research in Cancer Nanotechnology (IRCN), is a component of a broader program that is the NCI Alliance for Nanotechnology in Cancer. IRCN awards are designed to enable multidisciplinary research and transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address major barriers in cancer biology and/or oncology using nanotechnology and should emphasize fundamental understanding of nanomaterial and/or nanodevice interactions with biological systems. This scope includes research concerning the delivery of nanoparticles and/or nanodevices to desired and intended cancer targets in vivo and/or characterization of in vitro detection and diagnostic devices.

Application budgets are limited to $450K in direct costs per year and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: June 30, 2016; November 24, 2016; June 23, 2017; November 24, 2017, by 5:00 PM

 

National Cancer Institute (NCI)

Go to site...

Pediatric Cancer Research The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for research projects designed to use sound and innovative strategies to solve specific problems and paradoxes in childhood cancer research identified by the National Cancer Institute (NCI) as the NCI’s Pediatric Provocative Questions (Pediatric PQs). These problems and paradoxes framed as questions are not intended to represent the full range of NCI's priorities in childhood cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of pediatric cancer research that are deemed important but have not received sufficient attention. The FOA includes 9 Pediatric PQs that represent diverse fields relevant to childhood cancer research, but all are framed to inspire interested scientists to conceive new approaches and/or feasible solutions. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific Pediatric PQ selected from the list.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. Application budgets must reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

Date: June 30, 2016; November 24, 2016; June 23, 2017; November 24, 2017, by 5:00 PM

 

National Cancer Institute (NCI)

Go to site...

Pediatric Cancer Research The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for research projects designed to use sound and innovative strategies to solve specific problems and paradoxes in childhood cancer research identified by the National Cancer Institute (NCI) as the NCI’s Pediatric Provocative Questions (Pediatric PQs). These problems and paradoxes framed as questions are not intended to represent the full range of NCI's priorities in childhood cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of pediatric cancer research that are deemed important but have not received sufficient attention. The FOA includes 9 Pediatric PQs that represent diverse fields relevant to childhood cancer research, but all are framed to inspire interested scientists to conceive new approaches and/or feasible solutions. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific Pediatric PQ selected from the list.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: June 30, 2016; November 24, 2016; June 23, 2017; November 24, 2017, by 5:00 PM

 

National Institute of Nursing Research (NINR)

Go to site...

Investigator-Initiated Clinical Trials This Funding Opportunity Announcement (FOA) encourages applications that propose the complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The application should propose the developmental work to be performed that would enhance the probability of reaching definitive outcomes in a clinical trial.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to $150,000 direct costs. The scope of the proposed project should determine the project period. The maximum period is one year.

Date: March 24, 2017, July 24, 2017, November 24, 2017, March 23, 2018, July 24, 2018, November 26, 2018, March 25, 2019, July 24, 2019, November 25, 2019, by 5:00 PM

 

National Institute of Dental and Craniofacial Research (NIDCR)

Go to site...

HIV Pathogenesis in Oral Cavity This funding opportunity announcement (FOA) encourages hypothesis driven basic and translational sciences that will enhance our understanding of the role of microbiota in changing the immune response to HIV pathogenesis in the oral cavity.

NIDCR intends to commit $2 million in FY 2018 to fund 3-4 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years.

Date: November 24, 2017, by 5:00 PM

 

National Institute of Dental and Craniofacial Research (NIDCR)

Go to site...

Prophylactic Oral Mucosal Vaccine , HIV This Funding Opportunity Announcement (FOA) encourages hypothesis driven basic, translational and pre-clinical science research to develop novel approaches for prophylactic oral mucosal vaccine that will be synergistic with systemic vaccination for protection against HIV infection.

NIDCR intends to fund an estimate of 3-4 awards, corresponding to a total of $2 million, for fiscal year 2018. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years.

Date: November 24,2017, by 5:00 PM

 

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Go to site...

Maternal, Neonatal, Infant, and Early Childhood Morbidity and Mortality This funding opportunity announcement (FOA) invites applications from U.S. institutions to support Research Units (RUs) within the Global Network for Women’s and Children’s Health Research at NICHD.  RUs will consist of U.S.-based research centers applying in partnership with research centers in low income countries as defined by the World Bank.  The RUs within the Global Network will participate in addressing the major causes of maternal, neonatal, infant, and early childhood morbidity and mortality through the conduct of clinical research.  The grantees will become part of a cooperative network in scientific partnership with the NIH to conduct multi-enter observational studies and randomized clinical trials evaluating disease process, health and wellness outcomes, and results from interventions in resource-poor settings.

NICHD intends to commit approximately $4.8 million in total costs (direct plus Facilities and Administrative (F&A) costs) in FY 2018 to fund new and/or renewal awards. Applications for the RUs may request a budget for direct costs of up to $155,000 per year for RU base costs and $410,000 direct costs under Other Expenses as restricted funds, to be used for multiple protocols including a maternal neonatal health registry. Application budgets need to reflect actual needs of the proposed budget. Each RU applicant may request a project period of up to five years.

Date: November 27, 2017, by 5:00 PM

 

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Go to site...

Child Abuse and Neglect This funding opportunity announcement (FOA) will use the specialized research center mechanism (P50) to call for multidisciplinary centers to serve as the CAPSTONE for research on child abuse and neglect and to serve as a national resource for the field.  The Center(s) will conduct innovative and high quality research including: 1) trials testing the efficacy and effectiveness of clinical interventions;  2) longitudinal prospective studies examining the long term effects of specific and understudied types of maltreatment including abusive head trauma, medical child abuse and neglect, chronic sexual abuse; 3) studies examining the neurobiology of abuse and neglect and implications for health outcomes; and 4) studies testing the development of screening tools and clinical assessment measures for early identification and treatment of specific types of abuse and neglect to decrease morbidity and mortality and to identify potential comorbidities.  The Centers are also required to propose a community engagement core which will provide opportunities for students and faculty at all levels, to be exposed to cutting edge educational tools and technologies, research, and expertise within the field of child maltreatment. A central goal of this core will be to engage the scientific and lay professional communities in participatory activities such as technical assistance, evidence-based practice, participation in grand rounds, conferences and seminars, or webinars based on information emanating from the other cores.  The format for the community engagement activities will be tailored to the expertise of the Center and the needs of the community.    

The NICHD intends to commit $1.8 million dollars in FY 2018 to fund up to two awards. An application for a Center may request a budget of up to $1.2 million dollars in direct costs per year. The scope of the proposed Center should determine the project period. The maximum period is 5 years.

Date: November 27, 2017, by 5:00 PM

 

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Go to site...

Reproductive Sciences The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), through the Fertility and Infertility (FI) Branch, provides funding for a limited number of research centers in the reproductive sciences.  The purpose of this FOA is to announce the re-competition of the National Centers for Translational Research in Reproduction and Infertility (NCTRI). The NCTRI will be administered through the Specialized Research Center (P50) award mechanism. These centers will form a national network that facilitates and accelerates bidirectional knowledge transfer between the laboratory and clinic with the ultimate goal of improving human reproductive health through research excellence and innovation. For this FOA, applications that address the epigenetic bases of reproductive health and disease will be strongly encouraged.

The NICHD intends to commit $5,300,000 in FY 2018 to fund up to three awards in response to this FOA. An application for a center may request a budget for direct costs of no more than $1.2 million per year, excluding third party F&A. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: November 27, 2017, by 5:00 PM

 

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Go to site...

Population Dynamics The goal of this funding opportunity announcement (FOA) is to advance the field of population dynamics research by increasing research impact, innovation, and productivity; developing junior scientists; and maximizing the efficiency of research support.

NICHD intends to commit $1,000,000 in FY2018 to fund 4 to 6 awards. NICHD expects requested direct costs to range from $200,000 up to $500,000 per year. Requested annual direct costs may not exceed the lowest of the following:
• The Center's externally funded annual support for population dynamics research and training (direct costs).
• For new applications, maximum direct costs may not exceed $200,000.
• For renewal applications, requested increases may not exceed $125,000 more than the prior competitive award. However, maximum requested annual direct costs may not exceed $500,000. The total project period for an application submitted in response to this FOA may not exceed five years.

Date: November 27, 2017, by 5:00 PM

 

Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP), National Cancer Institute (NCI), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute on Minority Health and Health Disparities (NIMHD)

Go to site...

Electronic Nicotine Delivery Systems (ENDS), Tobacco The purpose of this funding opportunity announcement is to support studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations.

Direct costs are limited to $275,000 over a two-year project period, with no more than $200,000 in direct costs allowed in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

Date: November 27, 2017, by 5:00 PM

 

Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP), National Cancer Institute (NCI), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute on Minority Health and Health Disparities (NIMHD)

Go to site...

Electronic Nicotine Delivery Systems (ENDS), Tobacco The purpose of this funding opportunity announcement is to support studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: November 27, 2017, by 5:00 PM

 

Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP), National Cancer Institute (NCI), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS)

Go to site...

Electronic Nicotine Delivery Systems (ENDS) Aerosols The purpose of this funding opportunity announcement is to support basic research examining how Electronic Nicotine Delivery Systems (ENDS) aerosols affect normal and disease states relevant to human cells, tissues and organs.

Direct costs are limited to $275,000 over a two-year project period, with no more than $200,000 in direct costs allowed in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

Date: November 27, 2017; June 27, 2018; October 24, 2018; June 27, 2019; October 24, 2019; June 27, 2020, by 5:00 PM

 

Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP), National Cancer Institute (NCI), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS)

Go to site...

Electronic Nicotine Delivery Systems (ENDS) Aerosols The purpose of this funding opportunity announcement is to support basic research examining how Electronic Nicotine Delivery Systems (ENDS) aerosols affect normal and disease states relevant to human cells, tissues and organs.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: November 27, 2017; June 27, 2018; October 24, 2018; June 27, 2019; October 24, 2019; June 27, 2020, by 5:00 PM

 

National Cancer Institute (NCI)

Go to site...

Cancer This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research. The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for the NCI OIA. It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research.

Awards will be for $600,000 direct costs per year, plus applicable Facilities and Administrative (F&A) costs to be determined at the time of award. The total project period may not exceed 7 years.

Date: November 28, 2017, by 5:00 PM

 

Defense Health Program Congressionally Directed Medical Research Programs Spinal Cord Injury Research Program

Go to site...

Spinal Cord Injury (SCI) relevant to Military Populations The FY17 SCIRP CRDA is intended to support planning and development activities necessary to initiate a future clinical study with the potential to have a significant impact on SCIs. The future study to be developed through the CRDA may be clinical research or a clinical trial. Relevance of the research to military and/or Veteran populations affected by SCI is a key element of this award mechanism. Collaboration with military or VA researchers and clinicians is highly encouraged. Inclusion of active duty military or Veteran populations is very highly encouraged. If the research will involve other populations, the relevance to the military or Veteran populations and the rationale for the inclusion of the other populations must be clearly articulated by the applicant.

The maximum period of performance is 1 year. The anticipated direct costs budgeted for the entire period of performance will not exceed $100,000. The CDMRP expects to allot approximately $0.48M of the $30M FY17 SCIRP appropriation to fund approximately 3 Clinical Research Development Award applications, depending on the quality and number of applications received.

Date: 11:59 p.m. ET, November 29, 2017

 

Defense Health Program Congressionally Directed Medical Research Programs Spinal Cord Injury Research Program

Go to site...

Spinal Cord Injury (SCI) relevant to Military Populations The SCIRP CTA supports research with the potential to have a major impact on the treatment or management of SCI. Funding from this award mechanism must support a clinical trial and may not be used for preclinical research studies. Principal Investigators (PIs) seeking funding for a preclinical research project should consider one of the other award mechanisms/funding opportunities being offered. Involvement of junior investigators on the research team is encouraged.

The maximum period of performance is 4 years. The anticipated direct costs budgeted for the entire period of performance will not exceed $2,000,000. The CDMRP expects to allot approximately $12.8M of the $30M FY17 SCIRP appropriation to fund approximately 4 CTA applications, depending on the quality and number of applications received.

Date: 11:59 p.m. ET, November 29, 2017

 

Defense Health Program Congressionally Directed Medical Research Programs Spinal Cord Injury Research Program

Go to site...

Spinal Cord Injury (SCI) relevant to Military Populations The SCIRP IIRA is intended to support studies that have the potential to make an important contribution to SCI research, patient care, and/or quality of life. Applications must include preliminary and/or published data that is relevant to the mission of the SCIRP and the proposed research project. IIRA applications may focus on any phase of research from basic through translational. Permitted research includes preclinical studies in animal models, research with human subjects, or human anatomical substances, as well as correlative studies associated with an existing clinical trial. Clinical trials are not allowed under this funding opportunity.

The maximum period of performance is 3 years. The anticipated direct costs budgeted for the entire period of performance will not exceed $500,000. The CDMRP expects to allot approximately $4.8M of the $30M FY17 SCIRP appropriation to fund approximately 6 IIRA applications, depending on the quality and number of applications received.

Date: 11:59 p.m. ET, November 29, 2017

 

Defense Health Program Congressionally Directed Medical Research Programs Spinal Cord Injury Research Program

Go to site...

Spinal Cord Injury (SCI) relevant to Military Populations The intent of the Qualitative Research Award is to support qualitative research studies that will help researchers and clinicians better understand the experiences of individuals with SCI and thereby identify the most effective path(s) for adjusting to disability and/or improving overall quality of life, health, and functional status after SCI. This mechanism is specifically focused on military and Veteran populations in the years after SCI, examining the issues, barriers, and promoters of success for Service members during the transition from initial injury and acute care through rehabilitation and community reintegration; therefore, collaboration with military and VA researchers and clinicians is encouraged. Factors that may affect the rehabilitation and reintegration of spinal cord-injured Service members include, but are not limited to, age, gender, ethnicity, family members/caregivers, psychological health, severity of injury, type of medical care (e.g., civilian, VA, or military facility), and co-morbid conditions. A key feature of the QRA is the inclusion of military and/or Veteran populations in the years after SCI. Applicants should clearly describe how their study design, including recruitment strategies and access to appropriate populations, as applicable, will enable them to meet this intent.

The maximum period of performance is 3 years. The anticipated direct costs budgeted for the entire period of performance will not exceed $500,000. The CDMRP expects to allot approximately $2.4M of the $30M FY17 SCIRP appropriation to fund approximately 3 QRA applications, depending on the quality and number of applications received.

Date: 11:59 p.m. ET, November 29, 2017

 

Defense Health Program Congressionally Directed Medical Research Programs Spinal Cord Injury Research Program

Go to site...

Spinal Cord Injury (SCI) relevant to Military Populations The intent of the Qualitative Research Award is to support qualitative research studies that will help researchers and clinicians better understand the experiences of individuals with SCI and thereby identify the most effective path(s) for adjusting to disability and/or improving overall quality of life, health, and functional status after SCI. This mechanism is specifically focused on military and Veteran populations in the years after SCI, examining the issues, barriers, and promoters of success for Service members during the transition from initial injury and acute care through rehabilitation and community reintegration; therefore, collaboration with military and VA researchers and clinicians is encouraged. Factors that may affect the rehabilitation and reintegration of spinal cord-injured Service members include, but are not limited to, age, gender, ethnicity, family members/caregivers, psychological health, severity of injury, type of medical care (e.g., civilian, VA, or military facility), and co-morbid conditions. A key feature of the QRA is the inclusion of military and/or Veteran populations in the years after SCI. Applicants should clearly describe how their study design, including recruitment strategies and access to appropriate populations, as applicable, will enable them to meet this intent.    

Defense Health Program Congressionally Directed Medical Research Programs Spinal Cord Injury Research Program

Go to site...

Spinal Cord Injury (SCI) relevant to Military Populations The SCIRP TRA is intended to support translational research that will accelerate the movement of promising ideas in SCI research into clinical applications. Although not all-inclusive, some examples include demonstration studies of pharmaceuticals and medical devices in preclinical systems and/or clinical research on therapeutics, devices, or practice using human tissues or resources. Applications to the FY17 SCIRP TRA may include preclinical studies in animal models and clinical research involving human subjects and human anatomical substances. The FY17 SCIRP TRA may also support correlative studies that are associated with an ongoing or completed clinical trial and projects that optimize the design of future clinical trials.

The maximum period of performance is 3 years. Application submissions without an Optional Qualified Collaborator: The anticipated direct costs budgeted for the entire period of performance will not exceed $1,250,000. Application submissions with an Optional Qualified Collaborator: The anticipated direct costs budgeted for the entire period of performance will not exceed $1,500,000. The CDMRP expects to allot approximately $6M of the $30M FY17 SCIRP appropriation to fund approximately 3 TRA applications, depending on the quality and number of applications received.

Date: 11:59 p.m. ET, November 29, 2017

 

December 2017

ORGANIZATION / WEBSITE SPECIALTY
AREA
PURPOSE AWARD / DEADLINE
National Institute on Minority Health and Health Disparities (NIMHD), National Cancer Institute (NCI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), Division of Program Coordination, Planning and Strategic Initiatives: Tribal Health Research Office
Go to site...

Minority Health/Health Disparities in American Indian / Alaska Native (AI/AN) Populations. The purpose of this initiative is to support collaborative research between Tribal Epidemiology Centers and extramural investigators on topics related to minority health and health disparities in American Indian / Alaska Native (AI/AN) populations.

The combined budget for direct costs for the two year project period may not exceed $275,000. No more than $200,000 direct costs may be requested in any single year. The maximum project period is 2 years.

Date: December 4, 2017, December 4, 2018, December 4, 2019

National Institute on Minority Health and Health Disparities (NIMHD), National Cancer Institute (NCI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), Division of Program Coordination, Planning and Strategic Initiatives: Tribal Health Research Office
Go to site...
Minority Health/Health Disparities in American Indian / Alaska Native (AI/AN) Populations. The purpose of this initiative is to support collaborative research between Tribal Epidemiology Centers and extramural investigators on topics related to minority health and health disparities in American Indian / Alaska Native (AI/AN) populations.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to $350,000 direct costs/year. The maximum project period is 4 years.

Date: December 4, 2017, December 4, 2018, December 4, 2019

Defense Health Program Congressionally Directed Medical Research Programs Psychological Health/Traumatic Brain Injury Research Program
Go to site...
Applied Behavior Analysis (ABA) for individuals diagnosed with Autism Spectrum Disorder (ASD) The intent of the FY17 PH/TBIRP Applied Behavior Analysis Clinical Study (ABACS) Award is to support a prospective clinical study that will evaluate the effectiveness of the tiered delivery model of Applied Behavior Analysis (ABA) for individuals diagnosed with Autism Spectrum Disorder (ASD). It is envisioned that findings from the ABACS Award will lead to a thorough and detailed understanding of the outcomes of ABA services delivered to participants diagnosed with ASD who receive tiered model ABA services under the study. Importantly, it is anticipated that findings from the study will determine whether those receiving ABA services demonstrate improvements in cognitive and adaptive functioning.

The maximum period of performance is 4 years. The anticipated total costs (combined direct and indirect costs) budgeted for the entire period of performance will not exceed $7M. The CDMRP expects to allot approximately $7M of the FY17 PH/TBIRP appropriation to fund approximately one ABACS Award application, depending on the quality and number of applications received.

Date: 11:59 p.m. ET, December 14, 2017

Defense Health Program Congressionally Directed Medical Research Programs Breast Cancer Research Program Go to site... Breast Cancer, Innovative/Visionary Research The Innovator Award supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field including, but not limited to, breast cancer. The Innovator Award will provide these individuals with the funding and freedom to pursue their most novel, visionary, high-risk ideas that could accelerate progress to ending breast cancer. Because the intent of the Innovator Award mechanism is to recognize these remarkably creative and innovative visionary individuals, rather than projects, the central feature of the award is the innovative contribution that the Principal Investigator (PI) can make toward ending breast cancer. The PI should have a record of challenging the status quo, shifting paradigms by changing a field of research or approach to patient care, exhibiting high levels of creativity, and demonstrating promise for continued innovation in future work. These rare individuals will be able to articulate a vision for ending breast cancer that challenges current dogma and demonstrates an ability to look beyond tradition and convention. The PI is also expected to be established in his/her field and have demonstrated success at forming and leading effective partnerships and collaborations. To further the development of innovative individuals and spark the generation of novel ideas, applications are required to incorporate the mentoring of promising junior investigators.

The maximum period of performance is 4 years. The anticipated direct costs budgeted for the entire period of performance will not exceed $5M. The CDMRP expects to allot approximately $8.0M of the $120M FY17 BCRP appropriation to fund approximately 1 Innovator Award application, depending on the quality and number of applications received.

Date: 11:59 p.m. ET, December 21, 2017

Defense Health Program Congressionally Directed Medical Research Programs Breast Cancer Research Program Go to site... Breast Cancer The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, breast cancer, even if clinical impact is not an immediate outcome. Research Scope: Research proposed under this award mechanism may be small- to large-scale projects, at different stages of idea and research development. Two different funding levels, based on the scope of the research, are available under this Program Announcement. The current Program Announcement discusses Funding Levels 3 and 4. Funding Levels 1 and 2 will be available under a different Program Announcement (W81XWH-17-BCRP-BREAKTHROUGH2-
FL12).

Funding Level 3: The maximum period of performance is 4 years. The anticipated direct costs budgeted for the entire period of performance will not exceed $2.5M. Funding Level 3 with Partnering PI Option: The maximum period of performance is 4 years. The anticipated combined direct costs budgeted for the entire period of performance for the Initiating PI and each Partnering PI’s applications will not exceed $4M. Applications with a single PI or Partnering PI Option have the same funding limits. The maximum period of performance is 4 years. For applications submitted with a single PI: The anticipated direct costs budgeted for the entire period of performance will not exceed $10M. For applications submitted under the Partnering PI Option: The anticipated combined direct costs budgeted for the entire period of performance for the Initiating PI’s and Partnering PI’s applications will not exceed $10M. The CDMRP expects to allot approximately $26.4M of the $120M FY17 BCRP appropriation to fund approximately 3 Breakthrough Award Levels 3 and 4 applications, depending on the quality and number of applications received.

Date: 11:59 p.m. ET, December 21, 2017

Defense Health Program Congressionally Directed Medical Research Programs Breast Cancer Research Program Go to site... Breast Cancer The BCRP Distinguished Investigator Award enables established visionary leaders from any field to pursue innovative ideas that could accelerate progress toward ending breast cancer. These individuals should be exceptionally talented researchers who have shown that they are leaders in their field(s) through extraordinary creativity, vision, and productivity. The Principal Investigator (PI) is expected to have a renowned reputation as a researcher who has made groundbreaking contributions to advancing his/her field. He/she should have demonstrated success at forming and leading effective partnerships and collaborations. Through his/her distinguished record of research and leadership, the PI should demonstrate the potential to make unique and significant advances in breast cancer. The central feature of the Distinguished Investigator Award is that the PI must propose research that is a fundamental shift from his/her track record of research and addresses one or more BCRP overarching challenge(s). Applications that are a continuation or incremental change from the PI’s published line of research do not meet the intent of this award. High-risk/high-reward applications with limited preliminary data are welcomed, but not required. All applications must include a well-formulated, testable hypothesis based on strong scientific rationale.

The maximum period of performance is 4 years. The anticipated direct costs budgeted for the entire period of performance will not exceed $3M. The CDMRP expects to allot approximately $4.8M of the $120M FY17 BCRP appropriation to fund approximately 1 Distinguished Investigator Award application, depending on the quality and number of applications received.

Date: 11:59 p.m. ET, December 21, 2017

Defense Health Program Congressionally Directed Medical Research Programs Joint Program Committee-8/Clinical and Rehabilitative Medicine Research Program Psychological Health/Traumatic Brain Injury Research Program Go to site... Traumatic Brain Injury (TBI) The FY17/18 PH/
TBIRP CTRR–CRA Program Announcement supports applied and translational research to advance the development of knowledge and materiel products for rehabilitation and restoration of function following TBI. PIs should explain how their work will inform the development, refinement, and/or revision of existing standards of care, clinical recommendations, or guidelines.

The maximum period of performance is 4 years. The anticipated total costs budgeted for the entire period of performance will not exceed $2.0M. The JPC-8/CRMRP expects to allot approximately $8.0M of the FY17 PH/TBIRP appropriation and $2.0M of the anticipated FY18 PH/TBIRP appropriation to fund approximately 4 Clinical Research Award applications with FY17 funds and approximately 1 award with FY18 funds, depending on the quality and number of applications received.

Date: 11:59 p.m. ET, December 27, 2017

Defense Health Program Congressionally Directed Medical Research Programs Joint Program Committee-Clinical and Rehabilitative Medicine Research Program Psychological Health/Traumatic Brain Injury Research Program Go to site... Traumatic Brain Injury (TBI) The FY17/18 PH/
TBIRP CTRR–CTA supports clinical trials to advance the development of knowledge and materiel products for rehabilitation and restoration of function following TBI in Service members, Veterans, and other individuals with TBI. PIs should explain how their work will inform the development, refinement, and/or revision of existing standards of care, clinical recommendations, or guidelines. Clinical trials with alternative study designs such as pragmatic or practice-based trials will be considered in this category.

The maximum period of performance is 4 years. The anticipated total costs budgeted for the entire period of performance will not exceed: • $2.5M for awards responding to the Vestibular Rehabilitation and mechanisms of Recovery Focus Area. • $4.0M for awards responding to the Cognitive Rehabilitation Focus Area. The JPC-8/CRMRP expects to allot approximately $4.0M of the FY17 PH/TBIRP appropriation and $3.0M of the anticipated FY18 PH/TBIRP appropriation to fund approximately 2-3 Clinical Trial Award applications, depending on the quality and number of applications received.

Date: 11:59 p.m. ET, December 27, 2017

Defense Health Program Congressionally Directed Medical Research Programs Breast Cancer Research Program Go to site... Traumatic Brain Injury (TBI) The FY17/18 PH/
TBIRP CTRR–CTA supports clinical trials to advance the development of knowledge and materiel products for rehabilitation and restoration of function following TBI in Service members, Veterans, and other individuals with TBI. PIs should explain how their work will inform the development, refinement, and/or revision of existing standards of care, clinical recommendations, or guidelines. Clinical trials with alternative study designs such as pragmatic or practice-based trials will be considered in this category.

The maximum period of performance is 4 years. The anticipated total costs budgeted for the entire period of performance will not exceed: • $2.5M for awards responding to the Vestibular Rehabilitation and mechanisms of Recovery Focus Area. • $4.0M for awards responding to the Cognitive Rehabilitation Focus Area. The JPC-8/CRMRP expects to allot approximately $4.0M of the FY17 PH/TBIRP appropriation and $3.0M of the anticipated FY18 PH/TBIRP appropriation to fund approximately 2-3 Clinical Trial Award applications, depending on the quality and number of applications received.

Date: 11:59 p.m. ET, December 27, 2017

Defense Health Program Congressionally Directed Medical Research Programs Breast Cancer Research Program Go to site... Breast Cancer The Era of Hope Scholar Award supports individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer. These individuals should be exceptionally talented scientists who have shown that they are the “best and brightest” in their field(s) through extraordinary creativity, vision, innovation, and productivity. They should have demonstrated experience in forming effective partnerships and collaborations and must exhibit strong potential for future leadership in breast cancer research. As the intent of the Era of Hope Scholar Award is to recognize creative and innovative individuals rather than projects, the central features of the award are the applicant’s demonstrated ability to go beyond conventional thinking in their field and the innovative contribution that the Principal Investigator (PI) can make toward ending breast cancer. The PI should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention.

The maximum period of performance is 4 years. The anticipated direct costs budgeted for the entire period of performance will not exceed $2.5M. The CDMRP expects to allot approximately $4.0M of the $120M FY17 BCRP appropriation to fund approximately 1 Era of Hope Scholar Award application, depending on the quality and number of applications received.

Date: 11:59 p.m. ET, December 6, 2017

Defense Health Program Congressionally Directed Medical Research Programs Breast Cancer Research Program Go to site... Breast Cancer The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, breast cancer, even if clinical impact is not an immediate outcome. Research Scope: Research proposed under this award mechanism may be small- to large-scale projects, at different stages of idea and research development. Two different funding levels, based on the scope of the research, are available under this Program Announcement. The current Program Announcement discusses Funding Levels 1 and 2. Funding Levels 3 and 4 are available under a different Program Announcement (W81XWH-17-BCRP-BREAKTHROUGH2
-FL34).

Funding Level 1: The maximum period of performance is 3 years. The anticipated direct costs budgeted for the entire period of performance will not exceed $375,000. Funding Level 1 with Partnering PI Option: The maximum period of performance is 3 years. The anticipated combined direct costs budgeted for the entire period of performance for the Initiating PI’s and the Partnering PI’s applications will not exceed $600,000. Funding Level 2: The maximum period of performance is 3 years. The anticipated direct costs budgeted for the entire period of performance will not exceed $750,000. Funding Level 2 with Partnering PI Option: The maximum period of performance is 3 years. The anticipated combined direct costs budgeted for the entire period of performance for the Initiating PI’s and the Partnering PI’s applications will not exceed $1M. The CDMRP expects to allot approximately $20M of the $120M FY17 BCRP appropriation to fund approximately 20 Breakthrough Award Levels 1 and 2 applications, depending on the quality and number of applications received.

Date: 11:59 p.m. ET, December 6, 2017

Defense Health Program Congressionally Directed Medical Research Programs Breast Cancer Research Program Go to site... Breast Cancer The Breakthrough Fellowship Award supports recent doctoral or medical graduates in pursuit of innovative, high-impact breast cancer research during their postdoctoral fellowship and allows them to obtain the necessary experience for an independent career at the forefront of breast cancer research. Those individuals should be exceptionally talented researchers who have demonstrated that they are the “best and brightest” of their peers. Applicants for this award must exhibit a strong desire to pursue a career in breast cancer research, with clear evidence for a researcher development plan that will lead to a successful independent career in breast cancer. Applicants must also demonstrate that the proposed research has high potential to lead to or make breakthroughs in breast cancer.

The maximum period of performance is 3 years. The anticipated direct costs budgeted for the entire period of performance will not exceed $300,000. The CDMRP expects to allot approximately $2.4M of the $120M FY17 BCRP appropriation to fund approximately 5 Breakthrough Fellowship Award applications, depending on the quality and number of applications received.

Date: 11:59 p.m. ET, December 6, 2017

Defense Health Program Congressionally Directed Medical Research Programs Reconstructive Transplant Research Program Go to site... Reconstructive Transplant Research, Innovative/Untested Research The intent of the FY17 RTRP Concept Award is to support the exploration of a highly innovative new concept or untested theory that addresses an important problem relevant to reconstructive transplantation. The Concept Award is not intended to support a logical progression of an already established research project, but instead, supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Young/early-career investigators are encouraged to apply.

The maximum period of performance is 18 months. The anticipated total costs (direct and indirect) budgeted for the entire period of performance will not exceed $200,000. The CDMRP expects to allot approximately $1M of the $12M FY17 RTRP appropriation to fund approximately five Concept Award applications, depending on the quality and number of applications received. The CDMRP expects to allot approximately $1M of the $12M FY17 RTRP appropriation to fund approximately five Concept Award applications, depending on the quality and number of applications received.

Date: 11:59 p.m. ET, December 6, 2017

Defense Health Program Congressionally Directed Medical Research Programs Reconstructive Transplant Research Program Go to site... Reconstructive Transplant Research The FY17 RTRP Investigator-Initiated Research Award is intended to support studies that have the potential to make an important contribution to reconstructive transplant research, patient care, and/or quality of life. Multi-institutional collaborations among clinicians and research scientists are encouraged. Investigator-Initiated Research Award applications may focus on any phase of research from basic through translational, including preclinical studies in animal models or human subjects, as well as correlative studies associated with an existing clinical trial. Clinical trials are not allowed under this funding opportunity.

The maximum period of performance is 3 years. Single PI: The anticipated total costs (direct and indirect) budgeted for the entire period of performance will not exceed $1M for Single PI submissions. Multiple PI Option: The anticipated combined total costs (direct and indirect) budgeted for the entire period of performance for the Initiating PI and all Partnering PIs’ applications will not exceed $1.5M. The CDMRP expects to allot approximately $4M of the $12M FY17 RTRP appropriation to fund approximately three Investigator-Initiated Research Award applications, depending on the quality and number of applications received.

Date: 11:59 p.m. ET, December 6, 2017

Defense Health Program Congressionally Directed Medical Research Programs Reconstructive Transplant Research Program Go to site... Reconstructive Transplant Research, Translational Research The FY17 RTRP Technology Development Award is intended to support research critical for the translation of promising preclinical findings into products focused on reconstructive transplantation. Proposed research and products to be developed may be materiel products such as drugs, biologic agents, or devices, or knowledge-based products such as technical reports and clinical practice guidelines that inform clinical/operational decisions and promote evidence-based changes in clinical practice and standard of care.

The maximum period of performance is 3 years. The anticipated total costs (direct and indirect) budgeted for the entire period of performance will not exceed $1M. The CDMRP expects to allot approximately $2M of the $12M FY17 RTRP appropriation to fund approximately two Technology Development Award applications, depending on the quality and number of applications received.

Date: 11:59 p.m. ET, December 6, 2017

Defense Health Program Congressionally Directed Medical Research Programs Reconstructive Transplant Research Program Go to site... Reconstructive Transplant Research, Qualitative Research Studies The intent of the FY17 RTRP Qualitative Research Award is to support qualitative research studies that will help researchers and clinicians better understand the experiences of individuals involved in the reconstructive transplant process. This includes those who are considering, or who have already received, reconstructive transplant surgery and/or the reality of lifelong immunosuppression, as well as caregivers, potential donors and their families, and even the clinicians themselves. This understanding will, in turn, support the ultimate goal of improving transplant outcomes and the quality of life for individuals who receive these life-changing procedures.

The maximum period of performance is 3 years. Single PI: The anticipated total costs (direct and indirect) budgeted for the entire period of performance will not exceed $1M for Single PI submissions. Multiple PI Option: The anticipated combined total costs (direct and indirect) budgeted for the entire period of performance for the Initiating PI and all Partnering PIs’ applications will not exceed $1.5M. The CDMRP expects to allot approximately $4M of the $12M FY17 RTRP appropriation to fund approximately three Qualitative Research Award applications, depending on the quality and number of applications received.

Date: 11:59 p.m. ET, December 6, 2017

Fogarty International Center (FIC), National Institute of Mental Health (NIMH) Go to site... Interventions to Reduce HIV/AIDS-Associated Stigma in Low and Middle-Income Countries (LMICs)  The purpose of this FOA is to stimulate research on interventions to reduce HIV/AIDS-associated stigma and its impact on the prevention and treatment of HIV/AIDS and on the quality of life of People Living with HIV/AIDS (PLWH). Specifically, this initiative will support research on a) novel stigma reduction interventions that link to increase in care-seeking behavior and/or decrease in transmission; b) reducing the impact of stigma on adolescent and/or youth health; c) strategies to cope with the complex burden of stigmatization due to HIV and one or more comorbidities/
coinfections; d) reducing effects of stigma on and/or by family members or caregivers of PLWH; and e) innovative and improved stigma measurement in the context of implementation of an intervention. The overall goals are to understand how to reduce stigma as a factor in HIV transmission, to eliminate or mitigate the aspects of stigma that limit beneficial health outcomes for the infected and at-risk individuals and communities, and to initiate exploratory studies to determine the feasibility of stigma interventions related to HIV prevention, treatment and/or care in Low and Middle-Income Countries (LMICs).

Application budgets are limited to up to $125,000 per year in direct costs, but need to reflect the actual needs of the proposed project. Applicants may request a project period of up to two years.

Date: December 11, 2017, by 5:00 PM

NIH Blueprint for Neuroscience Research (http://neuroscience
blueprint.
nih.gov/), National Center for Advancing Translational Sciences (NCATS), National Center for Complementary and Integrative Health (NCCIH), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS) Go to site...
CNS Small Blood and Lymphatic Vessels This Funding Opportunity Announcement (FOA) will solicit research projects focused on the development of new technology and tools, or novel mechanistic studies, or a combination of mechanistic and technology development studies specific to central nervous system (CNS, which includes retina) small blood and lymphatic vessels in health and disease, across the life span.  The program aims at facilitating the development of tools and technology to image, profile and map CNS small blood and lymphatic vessels.  Additional goals are to elucidate the mechanisms underlying CNS small blood and lymphatic vessels structural and functional heterogeneity, differential susceptibility to injury, role in disease and repair processes, and their responses to therapies. Preclinical studies using in vitro and/or animal models specific to CNS small blood and lymphatic vessels alone or in combination with pilot human studies are appropriate for this FOA.

NIH Blueprint for Neuroscience Research intends to fund up to 20 awards, corresponding to a total of $ 6 million, for fiscal year 2018, for this and the related FOA (RFA-NS-18-004) "Human Studies of Target Identification, Biomarkers and Disease Mechanisms Specific to CNS Small Blood and Lymphatic Vessels". Future year amounts will depend on annual appropriations. Application budgets are limited to $400,000 direct costs/year and need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Date: December 11, 2017, by 5:00 PM

NIH Blueprint for Neuroscience Research (http://neuroscience
blueprint.
nih.gov/), National Center for Advancing Translational Sciences (NCATS), National Center for Complementary and Integrative Health (NCCIH), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR) Go to site...
CNS Small Blood and Lymphatic Vessels This Funding Opportunity Announcement (FOA) will solicit research projects to facilitate the development and translation of tools and technology for non-invasive imaging and profiling of human central nervous system (CNS, including retina) small blood and lymphatic vessels; to investigate their role in CNS physiology, disease, repair processes, and responses to therapy using novel approaches. Applications can be focused on the development of new technology and tools, novel target or biomarker identification and validation studies, or a combination of mechanistic and technology development studies specific to human CNS small blood and lymphatic vessels in health and disease, across the life span.  

NIH Blueprint for Neuroscience Research intends to fund up to 20 awards, corresponding to a total of $ 6 million, for fiscal year 2018, for this and the related FOA (RFA-NS-18-003) "Innovative Approaches or Technologies to investigate Regional, Structural and Functional Heterogeneity of CNS Small Blood and Lymphatic Vessels". Future year amounts will depend on annual appropriations. Application budgets are limited to $499,000 direct costs/year and need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Date: December 11, 2017, by 5:00 PM

National Institute on Drug Abuse (NIDA) Go to site... HIV, Substance Use Disorders (SUDs) This initiative will support exploratory projects that exploit HIV or host genomic or nucleomic information to understand HIV latency in individuals with substance use disorders (SUDs).

NIDA intends to commit $2 million dollars in FY2018 to fund 3-4 awards. Application budgets are limited to $650,000 direct costs and must reflect the actual needs of the proposed project. Budget periods are limited to no more than three years for the R61 phase and no more than two years for the R33 phase.

Date: December 13, 2017, by 5:00 PM 

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA) Go to site... Pregnant Women with Opioid Use Disorder In this funding opportunity announcement (FOA), we invite prospective applicants to propose research addressing treatment of pregnant women with opioid use disorder and pharmacokinetic and pharmacodynamic studies of medications used for maternal treatment.

The following NIH components intend to commit the following amounts in FY 2018: NICHD intends to commit $1.5 million in total costs in FY 2018 to fund 2-3 awards. NIDA intends to commit $500,000 in total costs in FY 2018 to fund 1-2 awards. Application budgets are limited to $500,000 in direct costs. The maximum project period is 5 years.

Date: December 13, 2017, by 5:00 PM 

NIH Blueprint for Neuroscience Research (http://neuroscience
blueprint.
nih.gov), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Center for Complementary and Integrative Health (NCCIH), Office of Behavioral and Social Sciences Research (OBSSR) Go to site...
Neuroscience The purpose of the NIH Blueprint Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award is to support a defined pathway across career stages for outstanding graduate students who are from backgrounds that are nationally underrepresented in neuroscience research. This two-phase award will facilitate completion of the doctoral dissertation and transition of talented graduate students to strong neuroscience research postdoctoral positions, and will provide career development opportunities relevant to their long-term career goal of becoming independent neuroscience researchers.

The NIH Blueprint intends to commit $1M to fund approximately 20 awards. For the F99 phase, award budgets are composed of stipends, tuition and fees, and institutional allowance, as described below. For the K00 phase, award budgets are composed of salaries and fringe benefits, research and career development support, and indirect costs, as described below. For the F99/K00 award, individuals may receive up to 6 years combined support for both phases, which includes up to 2 years in the F99 fellowship phase and up to 4 years in the K00 career development phase.

Date: December 13, 2017, by 5:00 PM 

Fogarty International Center (FIC), National Cancer Institute (NCI), National Human Genome Research Institute (NHGRI), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), Office of Research on Women's Health (ORWH) Go to site... Mentored Research for LMIC Early Career Research Scientist The purpose of the Fogarty Emerging Global Leader Award is to provide research support and protected time (three to five years) to an early career research scientist from a low- or middle-income country (LMIC) who holds a junior faculty position at an LMIC academic or research institution, as defined by the World Bank (http://data.
worldbank.org/about/
countryclassifications/
country-and-lending-
groups, including “low-income,” “lower-middle-income,” and “upper-middle-income” countries). This intensive, mentored research career development experience is expected to lead to an independently funded research career at the LMIC institution or in another LMIC. This Funding Opportunity Announcement (FOA) invites applications from LMIC scientists from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of their country under the mentorship of LMIC and U.S. mentors.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Award budgets are composed of salary and other program-related expenses, as described below. The total project period should be a minimum of 3 years and may not exceed 5 years.

Date: December 14, 2016; December 14, 2017; and December 13, 2018, by 5:00 PM

National Institute on Drug Abuse (NIDA) Go to site... CD4+ T Cells, Anti-Retroviral Therapy, HIV  The purpose of this funding opportunity is to identify genetic and epigenetic factors that affect the recovery of the CD4+ T cells in response to anti-retroviral therapy in HIV infected people who inject drugs infected

NIDA intends to fund an estimate of 1 to 2 awards, corresponding to a total of $3,000,000 for fiscal year 2018. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. Application budgets may not exceed $2,000,000 in direct cost. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: December 14, 2017, by 5:00 PM

National Heart, Lung, and Blood Institute (NHLBI) Go to site... AIDS Co-Morbidities, Cell and Gene Therapies for HIV The goal of the K12 Institutional Career Development Program in HIV-related Heart, Lung, Blood, and Sleep (HLBS) research is to encourage institutions to develop and sustain programs that support inter-disciplinary, intensive mentored research training and career development for junior PhDs and MDs in AIDS co-morbidities as well as cell and gene therapies for HIV cure and prevention of HIV transfusion transmission.

 NHLBI intends to fund up to 8 awards, corresponding to total costs up to $800,000 in FY 2018, and up to $3,360,000 total costs per year for fiscal years 2019 through 2022. Application budgets may not exceed direct costs of $92,550 in FY2018, and may not exceed direct costs of $388,750 in fiscal years 2019 through 2022. The maximum project period allowed is 5 years.

Date: December 14, 2017, by 5:00 PM

National Institute on Alcohol Abuse and Alcoholism (NIAAA) Go to site... Alcohol-Related Brain Damage This Funding Opportunity Announcement (FOA) issued by the National Institute on Alcoholism and Alcohol Abuse (NIAAA), National Institutes of Health, is a limited competition FOA encouraging a resource project (R28) application from a center currently supported under an existing grant, entitled “Brain Tissue Resource Center for Alcohol Research” to (i) develop a “bank” of brain tissues (fresh-frozen and formalin-fixed) from alcoholic and control cases with confirmed clinical and pathological diagnoses, (ii) develop and promote a prospective brain donor program in Australia (“Using our Brains”) to enhance the “brain bank”, (iii) establish an associated DNA (blood) bank from the brain donor group, and (iv) invite research groups with an interest in alcohol-related brain damage to submit applications for studies using these tissues.

One award is anticipated. Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed five years.

Date: December 14, 2017, by 5:00 PM

National Institute on Drug Abuse (NIDA), National Cancer Institute (NCI), National Institute on Alcohol Abuse and Alcoholism (NIAAA) Go to site... Substance Use Prevention and Treatment Interventions and Services As part of the Collaborative Research on Addiction at NIH (CRAN) initiative, NIDA, NIAAA, and NCI join to issue this FOA. The purpose of this FOA is to support the development and testing of interventions, models, and/or frameworks that examine system-level implementation of evidence-based interventions, guidelines, or principles to improve the delivery, uptake, quality, and sustainability of substance use prevention and treatment interventions and services.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to $500,000 in direct costs (including consortium F&A) in any project year, and need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Date: December 15, 2016; July 18, 2017; November 13, 2017; July 17, 2018; November 13, 2018; July 17, 2019; November 13, 2019; July 17, 2020; November 13, 2020, by 5:00 PM

National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA) Go to site... Substance Use Prevention and Treatment Interventions and Services As part of the Collaborative Research on Addiction at NIH (CRAN) initiative, NIDA and NIAAA join to issue this FOA. The purpose of this FOA is to support the development and testing of interventions, models, and/or frameworks that examine system-level implementation of evidence-based interventions, guidelines, or principles to improve the delivery, uptake, quality, and sustainability of substance use prevention and treatment interventions and services.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Applicants may request direct costs of up to $450,000 over the three year project period. Although variations from year to year are permissible, in no case may any year be more than $225,000 in direct costs, and total direct costs for the entire project period may not exceed $450,000. The maximum project period is 3 years.

Date: December 15, 2016; July 18, 2017; November 13, 2017; July 17, 2018; November 13, 2018; July 17, 2019; November 13, 2019; July 17, 2020; November 13, 2020, by 5:00 PM

National Cancer Institute (NCI), National Eye Institute (NEI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Library of Medicine (NLM), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP), Office of Behavioral and Social Sciences Research (OBSSR), Office of Research on Women’s Health (ORWH), Office of Strategic Coordination (Common Fund) Go to site... Biomedical Data Science The purpose of this Funding Opportunity Announcement (FOA) is to support high quality and impactful conferences/scientific meetings that are convened by data science related organizations whose missions focus on biomedical data science. This FOA, which uses the NIH conference cooperative agreement program (U13), is part of the NIH-wide initiative, Big Data to Knowledge (BD2K). Data science related organizations have a critical role in advancing biomedical data science but often depend on meetings to carry out their work. This FOA will support high quality conferences or meetings that are relevant to the biomedical data science needs of the participating Institutes and Centers of the National Institutes of Health. For the purpose of this FOA, a conference is defined as a gathering, such as in the form of a symposium, seminar, scientific meeting, workshop, or any other organized and formal meeting where persons assemble to coordinate, exchange, and disseminate information, or to explore or clarify a defined subject, problem, or area of knowledge.  Applicants representing data science related organizations may request support for one or a series of meetings over multiple years that address areas of data science aligned with the goals of the NIH BD2K program.

NIH intends to fund approximately 4-5 awards, corresponding to $2,000,000 in total costs in fiscal year 2017. Since the nature and scope of the proposed conferences/scientific meetings will vary from application to application, it is anticipated that the size and duration of each award could vary. Application budget requests should reflect the actual needs for the proposed meeting(s) but must not exceed $470,000 annually in direct costs. The scope of the proposed conference(s)/scientific meeting(s) should determine the project period. The maximum project period is three years.

Date: December 15, 2016; November 31, 2018, by 5:00 PM

National Institute on Minority Health and Health Disparities (NIMHD) Go to site... Research Centers in Minority Institutions (RCMI) Program The purpose of the Research Centers in Minority Institutions (RCMI) Program is to expand the national capacity for research in the health sciences by providing cooperative agreement support to institutions that offer doctorate degrees in the health professions or in a health-related science and have a historical and current commitment to  educating underrepresented students, and for institutions that deliver health care services, providing clinical services to medically underserved communities. The primary goals of the RCMI specialized centers are to: (1) enhance institutional research capacity within the areas of basic biomedical, behavioral, and/or clinical research; (2) enable all levels of investigators to become more successful in obtaining competitive extramural support, especially from NIH, particularly on diseases that disproportionately impact minority and other health disparity populations; (3) foster environments conducive to career enhancement with a special emphasis on development of new and early career investigators; (4) enhance the quality of all scientific inquiry and promote research on minority health and health disparities; and (5) establish sustainable relationships with community-based organizations that will partner with the RCMI Institution.

NIMHD intends to commit $10,000,000 in FY 2018 to fund 3-5 awards. Applicants must focus on basic biomedical, behavioral, and/or clinical research areas. Budgets are limited to $3,000,000 or less in direct costs per year. While applications which include focus on all three research areas may request the full amount, it is anticipated that applications with focus on two research areas will request up to $2,250,000 in direct costs and those with focus on one research area will request up to $1,500,000. Significant justification is expected if requesting the maximum limit, or if making a request beyond the anticipated level for a one or two focus area application. This FOA will also provide up to $500,000 in direct costs for A&R in addition to the overall direct cost cap, only in year one of the award period, as a one-time cost expenditure for a center.   The scope of the proposed project should determine the project period.  The maximum project period is 5 years.

Date: December 15, 2017, by 5:00 PM

National Institute of Neurological Disorders and Stroke (NINDS) Go to site... Parkinson's Disease This Funding Opportunity Announcement (FOA) invites applications for the Morris K. Udall Centers of Excellence for Parkinson’s Disease Research program. The overarching goal of the specialized Udall Centers program is to establish a network of Centers that work collaboratively as well as independently to define the causes of and discover improved treatments for Parkinson’s disease (PD). A more immediate goal for each Center is to rapidly advance synergistic, interdisciplinary research programs while serving as national leaders in PD research.

The NINDS intends to commit up to $4,500,000 total costs in fiscal year (FY) 2018 to support up to two awards. Applicants may request up to $1,000,000 direct costs per year with the follow exception: applications containing a translational project and/or clinical component (i.e. clinical research project plus a clinical core) may request up to $1,500,000 direct costs per year. The project period is limited to 5 years.

Date: December 15, 2017, by 5:00 PM

National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), Office of Behavioral and Social Sciences Research (OBSSR), Office of Research on Women’s Health (ORWH) Go to site... Neural Systems and Circuits The purpose of this FOA is to promote the integration of experimental, analytic, and theoretical capabilities for large-scale analysis of neural systems and circuits. This FOA seeks applications for exploratory research studies that use new and emerging methods for large scale recording and manipulation of neural circuits across multiple brain regions. Applications should propose to elucidate the contributions of dynamic circuit activity to a specific behavioral or neural system. Applications should seek to understand circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating relevant dynamic patterns of neural activity and by measuring the resulting behaviors and/or perceptions.  Studies should incorporate rich information on cell-types, on circuit functionality and connectivity, and should be performed in conjunction with sophisticated analysis of complex, ethologically relevant behaviors. Applications should propose teams of investigators that seek to cross boundaries of interdisciplinary collaboration by bridging fields and linking theory and data analysis to experimental design. Exploratory studies supported by this FOA are intended to develop experimental capabilities and quantitative, theoretical frameworks in preparation for a future competition for larger-scale, multi-component, Team-Research Circuit Programs (U19) awards.

NIH BRAIN Initiative intends to commit $5.5M in FY 2018 to fund 5 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The project period must be three years.

Date: December 15, 2017, by 5:00 PM 

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR) Go to site... HIV Infection and Treatment in Women of Reproductive Age The purpose of this FOA is to address critical scientific questions on the clinical course of HIV infection and treatment in a large cohort of HIV-positive young women of reproductive age. This new research study will help to define and understand clinical outcomes over the course of young women's reproductive lives, including a focus on the effects of HIV and antiretroviral treatment during pregnancies and post-partum periods.

NICHD intends to commit $3,500,000 in FY 2018 to fund 1 award. The following NIH components intend to commit the following amounts in FY 2018: NICHD, $3,500,000; NIDCR, $750,000 to fund 1 award. Application budgets are limited to $2,500,000 Direct Costs but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: December 15, 2017, by 5:00 PM 

National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH) Go to site... Neuroscience, Brain Function This FOA solicits new theories, computational models, and statistical tools to derive understanding of brain function from complex neuroscience data.  Proposed tools could include the creation of new theories, ideas, and conceptual frameworks to organize/unify data and infer general principles of brain function; new computational models to develop testable hypotheses and design/drive experiments; and new mathematical and statistical methods to support or refute a stated hypothesis about brain function, and/or assist in detecting dynamical features and patterns in complex brain data.  It is expected that the tools developed under this FOA will be made widely available to the neuroscience research community for their use and modification.  Investigative studies should be limited to validity testing of the tools being developed.

Then NIH BRAIN initiative anticipates providing $6M per year to fund up to 15 awards each year. Application budgets not limited, but are expected to range between $150,000 to $250,000 direct costs per year. Awards are for three years of support.

Date: December 15, 2017; October 17, 2018; October 17, 2019,  by 5:00 PM

Center for Tobacco Products (CTP) Go to site... Tobacco Control Laws The Food and Drug Administration announces its intention to accept and consider a single source application for award to the World Health Organization (WHO) for the Building Research Capacity in Global Tobacco Product Regulation Program.  The purpose of the Program is to identify, support, develop, conduct, and coordinate research efforts relating to tobacco control laws and rules in foreign countries that will directly inform and support FDA’s exercise of its authority to regulate the manufacture, distribution, marketing and sale of tobacco products in the United States. The Program will advance FDA's Center for Tobacco Products' (CTP’s) mission by utilizing the World Health Organization’s (WHO) Member States’ expertise and extensive international contacts in global tobacco control, as well as WHO's own programmatic expertise, to inform and support adequate manufacture, distribution and market regulations of tobacco products for the protection of public health in the United States. The Program will also provide a universal public benefit by creating opportunities for collaboration and research development globally, thereby resulting in better-informed and effective tobacco product regulation around the world, and increased knowledge in the public sphere regarding tobacco use and its harms globally.

The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications.  FDA/CTP intends to fund one (1) award up to $450,000 for fiscal year 2018 in support of this cooperative agreement program (total costs including indirect costs for one award subject to availability of funds). FDA/CTP anticipates the possibility of four (4) additional years of support up to $1,800,000 of funding contingent upon successful performance and the availability of funding. Fiscal Year Funds: 2018; Estimated Current Fiscal Year (FY) Funding: $450,000;
Maximum Size Award in Current Fiscal Year: $450,000; Estimated Number of Awards: 1. Maximum Size Award in Future Years: FY 2019 ($450,000); FY 2020 ($450,000); FY 2021 ($450,000); FY 2022 ($450,000).Maximum Project Period: Five (5) Years. Application budgets need to reflect the actual needs of the proposed project and should not exceed the following in total costs (direct and indirect): YR 01: $450,000; YR 02: $450,000; YR 03: $450,000; YR 04: $450,000; YR 05: $450,000. The scope of the proposed project should determine the project period. The maximum project period is Five (5) years.

Date: December 18, 2017 by 11:59 PM Eastern Time

National Institute on Drug Abuse (NIDA) Go to site... Neuropathic Pain for HIV-infected patients exposed to Opioids The purpose of this RFA is to promote research investigating the underlying mechanisms by which opioids including prescription drugs exacerbate HIV-associated neuropathic pain. Results from these studies may help obtain information for developing safe and effective treatments of neuropathic pain for HIV-infected patients exposed to opioids. 

NIDA intends to fund an estimate of 4-5 grant awards, corresponding to a total of $3 M for fiscal year 2018. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project.  The direct cost of an application must be less than $500,000. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: December 18, 2017, by 5:00 PM

National Cancer Institute (NCI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Advancing Translational Sciences (NCATS), National Center for Emerging Zoonotic and Infectious Diseases (NCEZID/CDC), National Institute for Occupational Safety and Health (NIOSH/CDC) Go to site... Administrative Supplements This funding opportunity announcement (FOA) seeks to develop and nurture a national innovation ecosystem that builds upon biomedical research to develop technologies, products, and services that benefit society. Toward meeting this objective, the I-Corps™ program is being offered. The I-Corps™ at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. Under this FOA, participating NIH and CDC Institutes and Centers will continue providing administrative supplement awards to currently-funded SBIR and STTR Phase I grantees. The program is designed to provide three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH and Centers for Disease Control and Prevention (CDC) SBIR and STTR funding. It is anticipated that outcomes for the I-Corps™ teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact NIH or CDC Scientific/Research staff for more information about the program before applying.

NIH/CDC intends to commit up to $1,200,000 in FY 2018 to fund up to 24 awards. Application budgets are limited to no more than $50,000 in total direct costs, and must reflect the actual needs of the proposed project. The project and budget periods must be within the currently approved project period for the existing parent award.

Date: December 18, 2017, by 5:00 PM

National Cancer Institute (NCI) Go to site... Pediatric Immunotherapy Translational Science Network This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish Centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations. 

NCI intends to fund one or two awards, corresponding to a total of $4 million dollars in total costs for fiscal year 2018. Future year amounts will depend on annual appropriations. Application budgets are limited to $1.6 million in direct costs per year, and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: December 19, 2017, by 5:00 PM

National Cancer Institute (NCI) Go to site... Pediatric Immunotherapy Translational Science Network This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The overall goal of this FOA and the companion FOA, RFA-CA-17-050, is to establish a network of collaborating investigators to identify and advance research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications.   Specifically, this FOA targets the following area(s) designated as a scientific priority(ies) by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translation science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. This FOA solicits U01 applications for discrete research projects that address relevant research opportunities (e.g., mechanisms of immune evasion, model development, validation of a single target, etc.), while the companion FOA, RFA-CA-17-050, solicits multi-component U54 Center applications. Successful applicants from both FOAs will become members of the Pediatric Immunotherapy Discovery and Development Network (PI-DDN), which will address and implement the BRP recommendations.

NCI intends to fund six to 10 awards, corresponding to a total of $4 million dollars in total costs for fiscal year 2018. Future year amounts will depend on annual appropriations. Application budgets are limited to $500,000 in direct costs per year and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: December 19, 2017, by 5:00 PM

National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH) Go to site... Noninvasive Human Brain Imaging Technologies This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, aims to support early stage development of entirely new and novel noninvasive human brain imaging technologies and methods that will lead to transformative advances in our understanding of the human brain. The FOA solicits unusually bold and potentially transformative approaches and supports small-scale, proof-of-concept development based on exceptionally innovative, original and/or unconventional concepts. 

Issuing IC and partner components intend to commit an estimated total of $4M to fund 6-12 awards. Application budgets are limited to $300,000 in direct costs in any project year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

Date: December 20, 2017 and December 11, 2018, by 5:00 PM 

National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH) Go to site... Noninvasive Human Brain Imaging Technologies This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, aims to support full development of entirely new or next generation noninvasive human brain imaging tools and methods that will lead to transformative advances in our understanding of the human brain. The FOA seeks innovative applications that are ready for full-scale development of breakthrough technologies with the intention of delivering working tools within the timeframe of the BRAIN Initiative (“BRAIN 2025: A Scientific Vision,” http://braininitiative.
nih.gov/). This FOA represents the second stage of the tool/technology development effort that started with RFA-MH-14-217 and RFA-MH-15-200 

Issuing IC and partner components intend to commit an estimated total of $8M to fund 3-6 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Date: December 20, 2017 and December 11, 2018, by 5:00 PM 

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Minority Health and Health Disparities (NIMHD), Office of Behavioral and Social Sciences Research (OBSSR) Go to site... HIV in Young Adults in LMIC The purpose of this FOA is to stimulate much needed research in an important area of public health significance: prevention of new HIV infections among adolescents at risk, and the identification of, linkage to and retention in care of, and long term viral suppression among youth living with HIV in low-to-middle income countries.  These settings must have an HIV epidemic density defined by UNAIDS estimates as either a country 1) in which at least 200,000 people are living with HIV and the number has not decreased by more than 5% over the last 2 consecutive years of available data or 2) has an HIV prevalence of 3% or more. 

NICHD and partner components intend to commit an estimated total of $9,000,000 to fund approximately 8-9 awards for fiscal year 2018. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The project period may be up to 5 years: up to 2 years for the first phase (UG3) and up to 3 years for the second phase (UH3).

Date: December 22, 2017, by 5:00 PM

vvvvNational Institute on Alcohol Abuse and Alcoholism (NIAAA) Go to site... Alcohol Use Disorders This Funding Opportunity Announcement (FOA) invites applications for specialized Alcohol Research Centers using the P50 mechanism.  The overall purpose of the NIAAA Alcohol Research Center program is to provide leadership in conducting and fostering interdisciplinary, collaborative research on a wide variety of topics relevant to the Institute’s mission.  These topics include, but are not limited to: the nature, etiology, genetics, diagnosis, treatment, and prevention of alcohol use disorders and their biomedical, psychosocial, and economic consequences across the lifespan.  Centers also are regional or national resources that contribute to the development of new research methods, technologies and approaches that sustain innovative goal-directed research.

NIAAA intends to commit $ 7.2 M in FY 2018 to fund up to 4 awards. Applications may not exceed $1.15 million direct costs per year. Applications may request a project period of up to five years.

Date: December 5, 2017, by 5:00 PM

National Institute on Drug Abuse (NIDA) Go to site... Pain Detection technology  The purpose of this Small Business Innovation Research (SBIR) Funding Opportunity Announcement (FOA) is to develop a technology/device that objectively indicates the presence and level of pain.

NIH intends to fund an estimate of 6-8 awards, corresponding to a total of $3M, for fiscal year 2018.  Future year amounts will depend on annual appropriations. According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). According to statutory guidelines, award periods normally may not exceed 6 months for Phase I and 2 years for Phase II.

Date: December 5, 2017, by 5:00 PM

National Institute on Drug Abuse (NIDA) Go to site... Pain Detection technology  The purpose of this Small Business Technology Transfer (STTR) Funding Opportunity Announcement (FOA) is to develop a technology/device that objectively indicates the presence and level of pain

NIH intends to fund an estimate of 2-3 awards, corresponding to a total of $1M, for fiscal year 2018.  Future year amounts will depend on annual appropriations. According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). According to statutory guidelines, award periods normally may not exceed 1 year for Phase I and 2 years for Phase II.

Date: December 5, 2017, by 5:00 PM

This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (http://commonfund
.nih.gov/) through the Office of the NIH Director, Office of Strategic Coordination (http://dpcpsi.nih.gov/). The FOA will be administered by the National Institute on Drug Abuse (NIDA/NIH) (http://www.nida.
nih.gov) on behalf of the NIH. Go to site...
Experimental Medicine Approach to Behavior Change Research This Funding Opportunity Announcement (FOA) solicits competitive revision (formerly known as a competitive supplement) applications to NIH-supported clinical trials awarded as research project R01 grants. (See information about the new NIH clinical trial definition at https://osp.od.nih.gov/
clinical-research/clinical-
trials/.) The goal of the SOBC Program is to advance a mechanisms-focused, experimental medicine approach to behavior change research. The goal of this FOA is to accelerate the adaptation, validation, and translation of SOBC Research Network assays for use in ongoing clinical trials. This FOA calls for the integration of SOBC Research Network assays into active NIH-supported clinical trials of drugs, devices, procedures, or behavior modifications.

The NIH Common Fund intends to commit $5.25 million in FY 2018 and $5.25 million in FY 2019 collectively across RFA-RM-17-022, RFA-RM-17-023, RFA-RM-17-024, and RFA-RM-17-028 to fund a total of 10-20 applications, contingent upon receiving scientifically meritorious applications and availability of funds. Application budgets are limited to $500,000 per year in direct costs and should not exceed the budget of the parent award. The maximum project period is 2 years, but the project cannot extend beyond the end date of the parent award.

Date: December 5, 2017, by 5:00 PM

This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (http://commonfund.
nih.gov/) through the Office of the NIH Director, Office of Strategic Coordination (http://dpcpsi.nih.gov/). The FOA will be administered by the National Institute on Drug Abuse (NIDA/NIH) (http://www.nida.
nih.gov) on behalf of the NIH. Go to site...
Experimental Medicine Approach to Behavior Change Research This Funding Opportunity Announcement (FOA) solicits competitive revision (formerly known as a competitive supplement) applications to NIH-supported clinical trials awarded as research project U01 cooperative agreements. (See information about the new NIH clinical trial definition at (https://osp.od.
nih.gov/clinical-research/
clinical-trials/.) The goal of the SOBC Program is to advance a mechanisms-focused, experimental medicine approach to behavior change research. Funded projects in the SOBC Research Network  (https://commonfund.
nih.gov/behaviorchange/
fundedresearch) have developed experimental manipulations, assays, and/or measures (hereafter referred to as “assays” for brevity) to support an. This FOA calls for the integration of SOBC Research Network assays into active NIH-supported clinical trials of drugs, devices, procedures, or behavior modifications.

The NIH Common Fund intends to commit $5.25 million in FY 2018 and $5.25 million in FY 2019 collectively across RFA-RM-17-022, RFA-RM-17-023, RFA-RM-17-024, and RFA-RM-17-028 to fund a total of 10-20 applications, contingent upon receiving scientifically meritorious applications and availability of funds. Application budgets are limited to $500,000 per year in direct costs and should not exceed the budget of the parent award. The maximum project period is 2 years, but the project cannot extend beyond the end date of the parent award.

Date: December 5, 2017, by 5:00 PM

This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (http://commonfund.
nih.gov/) through the Office of the NIH Director, Office of Strategic Coordination (http://dpcpsi.nih.gov/). The FOA will be administered by the National Institute on Drug Abuse (NIDA/NIH) (http://www.nida.
nih.gov) on behalf of the NIH. Go to site...
Experimental Medicine Approach to Behavior Change Research This Funding Opportunity Announcement (FOA) solicits competitive revision (formerly known as a competitive supplement) applications to NIH-supported clinical trials awarded as research project R34 grants. (See information about the new NIH clinical trial definition at https://osp.od.nih.gov/
clinical-research/clinical-trials/.) The goal of the SOBC Program is to advance a mechanisms-focused, experimental medicine approach to behavior change research. Funded projects in the SOBC Research Network (https://commonfund.
nih.gov/behaviorchange/ fundedresearch) have developed experimental manipulations, assays, and/or measures (hereafter referred to as “assays” for brevity) to support an experimental medicine approach to behavior change researchThe goal of this FOA is to accelerate the adaptation, validation, and translation of SOBC Research Network assays for use in ongoing clinical trials. This FOA calls for the integration of SOBC Research Network assays into active NIH-supported clinical trials of drugs, devices, procedures, or behavior modifications. Date: December 5, 2017, by 5:00 PM

The NIH Common Fund intends to commit $5.25 million in FY 2018 and $5.25 million in FY 2019 collectively across RFA-RM-17-022, RFA-RM-17-023, RFA-RM-17-024, and RFA-RM-17-028 to fund a total of 10-20 applications, contingent upon receiving scientifically meritorious applications and availability of funds. Application budgets are limited to $225,000 per year in direct costs and should not exceed the budget of the parent award. The maximum project period is 2 years, but the project cannot extend beyond the end date of the parent award.

Date: December 7, 2017, by 5:00 PM

This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (http://commonfund.
nih.gov/) through the Office of the NIH Director, Office of Strategic Coordination (http://dpcpsi.nih.gov/). The FOA will be administered by the National Institute on Drug Abuse (NIDA/NIH) (http://www.nida.
nih.gov) on behalf of the NIH. Go to site...
Experimental Medicine Approach to Behavior Change Research This Funding Opportunity Announcement (FOA) solicits exploratory and developmental research project applications (R21) that will further the goal of the SOBC Program to advance a mechanisms-focused, experimental medicine approach to behavior change research. Funded projects in the SOBC Research Network have developed experimental manipulations, assays, and/or measures (hereafter referred to as “assays” for brevity) to support an experimental medicine approach to behavior change research. The goal of this announcement is to leverage SOBC Measures Repository assays of putative targets in self-regulation, stress reactivity and stress resilience, and interpersonal and social processes domains to (1) engage a selected putative target(s) / mechanism(s) of action or verify target engagement of the selected target(s) / mechanism(s) of action, and (2) test the degree to which engaging the putative target(s) / mechanism(s) of action produces a short-term desired change in a health behavior. Putative targets are the mechanisms or processes hypothesized to be malleable and play a causal role in producing behavior change, including medical regimen adherence.

The NIH Common Fund intends to commit $5.25 million in FY 2018 and $5.25 million in FY 2019 collectively across RFA-RM-17-022, RFA-RM-17-023, RFA-RM-17-024, and RFA-RM-17-028 to fund a total of 10-20 applications, contingent upon receiving scientifically meritorious applications and availability of funds. Direct costs for the 2-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. The maximum project period is 2 years.

Date: December 5, 2017, by 5:00 PM

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Go to site... Drug-induced Liver Injury Network (DILIN) The purpose of this Funding Opportunity Announcement is for a limited competition for clinical centers for the continuation of the Drug-induced Liver Injury Network (DILIN). The DILIN Clinical Centers are  the components of the Network to identify, enroll and clinically characterize patients eligible for the DILIN. The companion RFA (RFA-DK-17-510) seeks to continue the Data Coordinating Center for DILIN.

NIDDK intends to commit $2,140,000 in FY 2018 to fund six awards. Future year amounts will depend on annual appropriations. The awards to each Clinical Center will be up to $250,000 in direct costs. Patient Care Cost should not be included in the application as it will be administered and provided by the DCC for all the CC. Application budgets are not limited, but need to reflect actual needs of the proposed project. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The maximum project period is five years.

Date: December 5, 2017, by 5:00 PM